J Cancer Res Clin Oncol (2015) 141:563–568 DOI 10.1007/s00432-014-1839-4
ORIGINAL ARTICLE – CLINICAL ONCOLOGY
Comparison of Glasgow prognostic score and prognostic index in patients with advanced non‑small cell lung cancer Ai‑Gui Jiang · Hong‑Lin Chen · Hui‑Yu Lu
Received: 19 July 2014 / Accepted: 14 September 2014 / Published online: 26 September 2014 © Springer-Verlag Berlin Heidelberg 2014
Abstract Objectives Previous studies have shown that Glasgow prognostic score (GPS) and prognostic index (PI) are also powerful prognostic tool for patients with advanced nonsmall cell lung cancer (NSCLC). The aim of this study was to compare the prognostic value between GPS and PI. Methods We enrolled consecutive patients with advanced NSCLC in this prospective cohort. GPS and PI were calculated before the onset of chemotherapy. The prognosis outcomes included 1-, 3-, and 5-year progression-free survival and overall survival (OS). The performance of two scores in predicting prognosis was analyzed regarding discrimination and calibration. Results 138 patients were included in the study. The area under the receiver operating characteristic curve for GPS predicting 1-year DFS was 0.62 (95 % confidence interval (CI) 0.56–0.68, P 10 mg/L
≤35 g/L >35 g/L
1 1
≤10 mg/L >10 mg/L
2
>10 mg/L
≤35 g/L
2
>10 mg/L
>11 × 109 ≤11 × 109 >11 × 109
GPS 0. If only CRP was increased or albumin decreased, patients were allocated to the GPS 1, and patients in whom CRP was >10 mg/L and albumin level 60 years. 117 patients (84.8 %) were male. 67 (48.6 %) patients had squamous cell carcinoma, and 56 (59.6 %) had stage IV disease. 42 (30.4 %) patients were smokers, and 82 (59.5 %) patients had an ECOG performance status 0 or 1. Patients’ clinicopathological characteristics are listed in Table 2. In the 2–5 years follow-up, 2 patients (1.4 %) lost in 1-year, 9 patients (6.5 %) lost in 2-year, and 19 patients (13.8 %) lost in 5-year.
Table 2 Patients’ clinicopathological characteristics Characteristics
n
%
Total Age ≤60 >60 Gender Male Female Histological type Squamous cell carcinoma Adenocarcinoma Others Stage IIIB IV Smoking status Nonsmoker Smoker Performance status 0
138
100.0
75 63
54.3 45.7
117 21
84.8 15.2
67 48 23
48.6 34.8 16.7
55 83
39.9 60.1
96 42
69.6 30.4
35
25.4
1 2
47 32
34.1 23.2
3
24
17.4
A
The area under the ROC curve for GPS predicting 1-year DFS was 0.62 (95 % CI 0.56–0.68, P
ORIGINAL ARTICLE – CLINICAL ONCOLOGY
Comparison of Glasgow prognostic score and prognostic index in patients with advanced non‑small cell lung cancer Ai‑Gui Jiang · Hong‑Lin Chen · Hui‑Yu Lu
Received: 19 July 2014 / Accepted: 14 September 2014 / Published online: 26 September 2014 © Springer-Verlag Berlin Heidelberg 2014
Abstract Objectives Previous studies have shown that Glasgow prognostic score (GPS) and prognostic index (PI) are also powerful prognostic tool for patients with advanced nonsmall cell lung cancer (NSCLC). The aim of this study was to compare the prognostic value between GPS and PI. Methods We enrolled consecutive patients with advanced NSCLC in this prospective cohort. GPS and PI were calculated before the onset of chemotherapy. The prognosis outcomes included 1-, 3-, and 5-year progression-free survival and overall survival (OS). The performance of two scores in predicting prognosis was analyzed regarding discrimination and calibration. Results 138 patients were included in the study. The area under the receiver operating characteristic curve for GPS predicting 1-year DFS was 0.62 (95 % confidence interval (CI) 0.56–0.68, P 10 mg/L
≤35 g/L >35 g/L
1 1
≤10 mg/L >10 mg/L
2
>10 mg/L
≤35 g/L
2
>10 mg/L
>11 × 109 ≤11 × 109 >11 × 109
GPS 0. If only CRP was increased or albumin decreased, patients were allocated to the GPS 1, and patients in whom CRP was >10 mg/L and albumin level 60 years. 117 patients (84.8 %) were male. 67 (48.6 %) patients had squamous cell carcinoma, and 56 (59.6 %) had stage IV disease. 42 (30.4 %) patients were smokers, and 82 (59.5 %) patients had an ECOG performance status 0 or 1. Patients’ clinicopathological characteristics are listed in Table 2. In the 2–5 years follow-up, 2 patients (1.4 %) lost in 1-year, 9 patients (6.5 %) lost in 2-year, and 19 patients (13.8 %) lost in 5-year.
Table 2 Patients’ clinicopathological characteristics Characteristics
n
%
Total Age ≤60 >60 Gender Male Female Histological type Squamous cell carcinoma Adenocarcinoma Others Stage IIIB IV Smoking status Nonsmoker Smoker Performance status 0
138
100.0
75 63
54.3 45.7
117 21
84.8 15.2
67 48 23
48.6 34.8 16.7
55 83
39.9 60.1
96 42
69.6 30.4
35
25.4
1 2
47 32
34.1 23.2
3
24
17.4
A
The area under the ROC curve for GPS predicting 1-year DFS was 0.62 (95 % CI 0.56–0.68, P
